NeuroSense reports positive safety results of PrimeC in Alzheimer's Phase 2 study. Q1 2026 to reveal clinical outcomes.

Unusual Whales
2025.12.22 14:20
NeuroSense Therapeutics Ltd., a biotechnology company based in Cambridge, Massachusetts, is set to reveal clinical and biomarker outcomes in the first quarter of 2026. The company, listed on NASDAQ as NRSN, specializes in developing groundbreaking treatments for severe neurodegenerative conditions. Keep an eye out for the latest developments from NeuroSense as they continue to advance in their late-clinical stage trials.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer